search
Back to results

Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Placebo
SHR117887
Sponsored by
Jiangsu HengRui Medicine Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring SHR117887, Metformin,combination,PhaseII

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients diagnosed with type 2 diabetes mellitus
  • Patients have been treated with metformin for at least 8 weeks and be on a stable dose of at least 1500mg daily prior to the screening visit
  • HbA1C:≥7.5% and ≤11.0% at screeing visit and at the end of run-in period
  • Age:≥20 and ≤70 years
  • BMI(body mass index):≥20 and ≤35 kg/m2

Exclusion Criteria:

-

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Placebo Comparator

    Experimental

    Experimental

    Arm Label

    Placebo/Metformin

    SHR117887 (50mg q.d)/Metformin

    SHR117887 (100mg q.d)/Metformin

    Arm Description

    patients are administered oral tablets of placebo once daily and 500mg TID for 4 weeks at the run-in period. After randomized ,patients administer the drugs too.

    patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 50mg QD and metformin 500mg TID for 12 weeks.

    patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 100mg QD and metformin 500mg TID for 12 weeks.

    Outcomes

    Primary Outcome Measures

    Change From Baseline in HbA1c (Hemoglobin A1C) at Week 12

    Secondary Outcome Measures

    Percentage of Participants Achieving Less Than (<) 6.5% or <7% HbA1c Levels
    Change From Baseline in Fasting Plasma Glucose,insulin and C-peptide at Week 12
    Post-meal total and incremental glucose,insulin and C-peptide area under the curve at week 12
    Change From Baseline in Body Weight at Week 12

    Full Information

    First Posted
    November 8, 2013
    Last Updated
    November 18, 2013
    Sponsor
    Jiangsu HengRui Medicine Co., Ltd.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01984489
    Brief Title
    Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes
    Official Title
    A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SHR117887 in Combination Therapy With Metformin in Patients With Type 2 Diabetes Patients
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2013
    Overall Recruitment Status
    Completed
    Study Start Date
    June 2012 (undefined)
    Primary Completion Date
    May 2013 (Actual)
    Study Completion Date
    August 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Jiangsu HengRui Medicine Co., Ltd.

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    SHR117887 is a new dipeptidyl peptidase(DPP)-4 inhibitor. This study aims to evaluate the efficacy and safety of SHR117887 in combination therapy with Metformin in patients with Type 2 Diabetes in Metformin monotherapy Who have Inadequate Glycemic Control

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes
    Keywords
    SHR117887, Metformin,combination,PhaseII

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    120 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Placebo/Metformin
    Arm Type
    Placebo Comparator
    Arm Description
    patients are administered oral tablets of placebo once daily and 500mg TID for 4 weeks at the run-in period. After randomized ,patients administer the drugs too.
    Arm Title
    SHR117887 (50mg q.d)/Metformin
    Arm Type
    Experimental
    Arm Description
    patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 50mg QD and metformin 500mg TID for 12 weeks.
    Arm Title
    SHR117887 (100mg q.d)/Metformin
    Arm Type
    Experimental
    Arm Description
    patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 100mg QD and metformin 500mg TID for 12 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Type
    Drug
    Intervention Name(s)
    SHR117887
    Primary Outcome Measure Information:
    Title
    Change From Baseline in HbA1c (Hemoglobin A1C) at Week 12
    Time Frame
    12 weeks
    Secondary Outcome Measure Information:
    Title
    Percentage of Participants Achieving Less Than (<) 6.5% or <7% HbA1c Levels
    Time Frame
    12 weeks
    Title
    Change From Baseline in Fasting Plasma Glucose,insulin and C-peptide at Week 12
    Time Frame
    12 weeks
    Title
    Post-meal total and incremental glucose,insulin and C-peptide area under the curve at week 12
    Time Frame
    12 weeks
    Title
    Change From Baseline in Body Weight at Week 12
    Time Frame
    12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients diagnosed with type 2 diabetes mellitus Patients have been treated with metformin for at least 8 weeks and be on a stable dose of at least 1500mg daily prior to the screening visit HbA1C:≥7.5% and ≤11.0% at screeing visit and at the end of run-in period Age:≥20 and ≤70 years BMI(body mass index):≥20 and ≤35 kg/m2 Exclusion Criteria: -

    12. IPD Sharing Statement

    Learn more about this trial

    Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes

    We'll reach out to this number within 24 hrs